Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

656 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A prospective observational study of postoperative adjuvant chemotherapy for non-small cell lung cancer in elderly patients (≥ 75 years).
Yano T, Hamatake M, Tokunaga S, Okamoto T, Yamazaki K, Miura T, Nagayasu T, Sato M, Fukuyama S, Sugio K; Lung Oncology Group in Kyushu (LOGIK). Yano T, et al. Among authors: tokunaga s. Int J Clin Oncol. 2022 May;27(5):882-888. doi: 10.1007/s10147-022-02143-7. Epub 2022 Feb 25. Int J Clin Oncol. 2022. PMID: 35212829
Feasibility trial of adjuvant chemotherapy with paclitaxel and carboplatin after surgical resection in Japanese patients with non-small cell lung cancer: report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0501.
Maruyama R, Yoshino I, Tokunaga S, Ohta M, Kato M, Yoshimine H, Yamazaki K, Nakanishi Y, Ichinose Y. Maruyama R, et al. Among authors: tokunaga s. Gen Thorac Cardiovasc Surg. 2008 Feb;56(2):68-73. doi: 10.1007/s11748-007-0188-5. Epub 2008 Feb 24. Gen Thorac Cardiovasc Surg. 2008. PMID: 18297461 Clinical Trial.
Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer-LOGIK 0601 study.
Yano T, Yamazaki K, Maruyama R, Tokunaga S, Shoji F, Higashi H, Takeo S, Ichinose Y, Maehara Y; Lung Oncology Group in Kyushu (LOGIK). Yano T, et al. Among authors: tokunaga s. Lung Cancer. 2010 Feb;67(2):184-7. doi: 10.1016/j.lungcan.2009.03.028. Epub 2009 May 5. Lung Cancer. 2010. PMID: 19409643 Clinical Trial.
Clinical efficacy and safety of cefepime in febrile neutropenic patients with lung cancer.
Fujita M, Ouchi H, Inoue Y, Inoshima I, Ohshima T, Yoshimura C, Wataya H, Kawasaki M, Tokunaga S, Nakanishi Y; Lung Oncology Group in Kyushu (LOGIK). Fujita M, et al. Among authors: tokunaga s. J Infect Chemother. 2010 Apr;16(2):113-7. doi: 10.1007/s10156-010-0030-3. Epub 2010 Feb 4. J Infect Chemother. 2010. PMID: 20130951 Clinical Trial.
Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients.
Emi Y, Kakeji Y, Oki E, Saeki H, Ando K, Kitazono M, Sakaguchi Y, Morita M, Samura H, Ogata Y, Akagi Y, Natsugoe S, Shirouzu K, Tokunaga S, Sirzen F, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Emi Y, et al. Among authors: tokunaga s. Int J Clin Oncol. 2013 Apr;18(2):254-9. doi: 10.1007/s10147-011-0371-7. Epub 2012 Jan 13. Int J Clin Oncol. 2013. PMID: 22240888
Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701).
Oki E, Emi Y, Akagi Y, Tokunaga S, Sadanaga N, Tanaka T, Ogata Y, Saeki H, Kakeji Y, Baba H, Nishimaki T, Natsugoe S, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer. Oki E, et al. Among authors: tokunaga s. Oncology. 2013;84(4):233-9. doi: 10.1159/000346690. Epub 2013 Jan 31. Oncology. 2013. PMID: 23392220 Clinical Trial.
Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.
Takayama K, Inoue K, Tokunaga S, Matsumoto T, Oshima T, Kawasaki M, Imanaga T, Kuba M, Takeshita M, Harada T, Shioyama Y, Nakanishi Y. Takayama K, et al. Among authors: tokunaga s. Cancer Chemother Pharmacol. 2013 Dec;72(6):1353-9. doi: 10.1007/s00280-013-2335-2. Epub 2013 Oct 29. Cancer Chemother Pharmacol. 2013. PMID: 24166107 Clinical Trial.
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).
Miwa K, Oki E, Emi Y, Saeki H, Kusumoto T, Akagi Y, Ogata Y, Samura H, Tokunaga S, Ishikawa H, Tanaka T, Sueyoshi S, Higashi H, Matsuda H, Touyama T, Maehara Y; Kyushu Study Group of Clinical Cancer. Miwa K, et al. Among authors: tokunaga s. Int J Clin Oncol. 2016 Feb;21(1):110-7. doi: 10.1007/s10147-015-0850-3. Epub 2015 Jun 3. Int J Clin Oncol. 2016. PMID: 26037783 Clinical Trial.
Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002).
Oki E, Emi Y, Miyamoto Y, Kabashima A, Higashi H, Ogata Y, Ikebe M, Saeki H, Tokunaga S, Shirabe K, Beppu T, Uchida S, Takatsuki M, Sakoda M, Eguchi S, Akagi Y, Kakeji Y, Baba H, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Oki E, et al. Among authors: tokunaga s. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1067-74. doi: 10.1245/s10434-015-4771-1. Epub 2015 Sep 3. Ann Surg Oncol. 2015. PMID: 26334293 Clinical Trial.
656 results